Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial.

Conclusions: Patients expressed a significantly greater treatment preference for once-daily alogliptin than once-weekly trelagliptin, although patient satisfaction and HbA1c levels were similar across treatments. The decision to administer a once-weekly or once-daily DPP-4i is likely to depend on patient preference, patient-physician discussions, and treatment practices of the prescribing physician. PMID: 31366262 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31366262?dopt=Abstract

Source: Current Medical Research and Opinion - August 3, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research